nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—RAF1—malignant glioma	0.415	0.591	CbGaD
Vemurafenib—BRAF—malignant glioma	0.287	0.409	CbGaD
Vemurafenib—CYP1A2—Carmustine—malignant glioma	0.0732	0.57	CbGbCtD
Vemurafenib—CYP3A4—Temozolomide—malignant glioma	0.0553	0.43	CbGbCtD
Vemurafenib—ORM1—vertebral column—malignant glioma	0.00293	0.19	CbGeAlD
Vemurafenib—VIIth nerve paralysis—Carmustine—malignant glioma	0.00198	0.0656	CcSEcCtD
Vemurafenib—Cyst—Carmustine—malignant glioma	0.00121	0.0403	CcSEcCtD
Vemurafenib—Hepatotoxicity—Carmustine—malignant glioma	0.00105	0.0349	CcSEcCtD
Vemurafenib—RAF1—embryo—malignant glioma	0.00104	0.0672	CbGeAlD
Vemurafenib—Hepatotoxicity—Temozolomide—malignant glioma	0.00102	0.0337	CcSEcCtD
Vemurafenib—Rigors—Temozolomide—malignant glioma	0.000961	0.0319	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.000954	0.0316	CcSEcCtD
Vemurafenib—RAF1—brainstem—malignant glioma	0.000951	0.0616	CbGeAlD
Vemurafenib—BRAF—midbrain—malignant glioma	0.00091	0.0589	CbGeAlD
Vemurafenib—RAF1—telencephalon—malignant glioma	0.000844	0.0546	CbGeAlD
Vemurafenib—Musculoskeletal pain—Temozolomide—malignant glioma	0.000794	0.0263	CcSEcCtD
Vemurafenib—Etoricoxib—PTGS2—malignant glioma	0.000748	1	CrCbGaD
Vemurafenib—Neoplasm—Carmustine—malignant glioma	0.000734	0.0243	CcSEcCtD
Vemurafenib—Neoplasm—Temozolomide—malignant glioma	0.000709	0.0235	CcSEcCtD
Vemurafenib—BRAF—cerebellum—malignant glioma	0.000704	0.0456	CbGeAlD
Vemurafenib—RAF1—medulla oblongata—malignant glioma	0.000663	0.0429	CbGeAlD
Vemurafenib—RAF1—midbrain—malignant glioma	0.000606	0.0392	CbGeAlD
Vemurafenib—RAF1—spinal cord—malignant glioma	0.000591	0.0383	CbGeAlD
Vemurafenib—BRAF—brain—malignant glioma	0.000572	0.037	CbGeAlD
Vemurafenib—Dry skin—Temozolomide—malignant glioma	0.000522	0.0173	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000513	0.017	CcSEcCtD
Vemurafenib—RAF1—central nervous system—malignant glioma	0.00048	0.0311	CbGeAlD
Vemurafenib—RAF1—cerebellum—malignant glioma	0.000469	0.0304	CbGeAlD
Vemurafenib—Photosensitivity reaction—Temozolomide—malignant glioma	0.000449	0.0149	CcSEcCtD
Vemurafenib—Weight decreased—Temozolomide—malignant glioma	0.000445	0.0148	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Carmustine—malignant glioma	0.000445	0.0148	CcSEcCtD
Vemurafenib—Infestation NOS—Temozolomide—malignant glioma	0.000439	0.0145	CcSEcCtD
Vemurafenib—Infestation—Temozolomide—malignant glioma	0.000439	0.0145	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000435	0.0144	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Temozolomide—malignant glioma	0.00043	0.0143	CcSEcCtD
Vemurafenib—ABCC1—telencephalon—malignant glioma	0.000422	0.0273	CbGeAlD
Vemurafenib—ORM1—spinal cord—malignant glioma	0.000408	0.0264	CbGeAlD
Vemurafenib—Oedema peripheral—Carmustine—malignant glioma	0.000402	0.0133	CcSEcCtD
Vemurafenib—Connective tissue disorder—Carmustine—malignant glioma	0.000401	0.0133	CcSEcCtD
Vemurafenib—Oedema peripheral—Temozolomide—malignant glioma	0.000388	0.0129	CcSEcCtD
Vemurafenib—Connective tissue disorder—Temozolomide—malignant glioma	0.000387	0.0128	CcSEcCtD
Vemurafenib—Eye disorder—Carmustine—malignant glioma	0.000381	0.0126	CcSEcCtD
Vemurafenib—RAF1—brain—malignant glioma	0.000381	0.0247	CbGeAlD
Vemurafenib—Erythema multiforme—Temozolomide—malignant glioma	0.000373	0.0123	CcSEcCtD
Vemurafenib—Eye disorder—Temozolomide—malignant glioma	0.000368	0.0122	CcSEcCtD
Vemurafenib—Cardiac disorder—Temozolomide—malignant glioma	0.000366	0.0121	CcSEcCtD
Vemurafenib—Alopecia—Carmustine—malignant glioma	0.00036	0.0119	CcSEcCtD
Vemurafenib—Angiopathy—Temozolomide—malignant glioma	0.000357	0.0118	CcSEcCtD
Vemurafenib—Mediastinal disorder—Temozolomide—malignant glioma	0.000355	0.0118	CcSEcCtD
Vemurafenib—Erythema—Carmustine—malignant glioma	0.000355	0.0118	CcSEcCtD
Vemurafenib—Malnutrition—Carmustine—malignant glioma	0.000355	0.0118	CcSEcCtD
Vemurafenib—Chills—Temozolomide—malignant glioma	0.000354	0.0117	CcSEcCtD
Vemurafenib—ABCG2—telencephalon—malignant glioma	0.000349	0.0226	CbGeAlD
Vemurafenib—Alopecia—Temozolomide—malignant glioma	0.000348	0.0115	CcSEcCtD
Vemurafenib—Back pain—Carmustine—malignant glioma	0.000343	0.0114	CcSEcCtD
Vemurafenib—Erythema—Temozolomide—malignant glioma	0.000343	0.0114	CcSEcCtD
Vemurafenib—Malnutrition—Temozolomide—malignant glioma	0.000343	0.0114	CcSEcCtD
Vemurafenib—Dysgeusia—Temozolomide—malignant glioma	0.000336	0.0111	CcSEcCtD
Vemurafenib—Back pain—Temozolomide—malignant glioma	0.000332	0.011	CcSEcCtD
Vemurafenib—ORM1—central nervous system—malignant glioma	0.000331	0.0214	CbGeAlD
Vemurafenib—Myalgia—Carmustine—malignant glioma	0.000302	0.01	CcSEcCtD
Vemurafenib—Cough—Temozolomide—malignant glioma	0.000299	0.00992	CcSEcCtD
Vemurafenib—Myalgia—Temozolomide—malignant glioma	0.000292	0.00968	CcSEcCtD
Vemurafenib—Arthralgia—Temozolomide—malignant glioma	0.000292	0.00968	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00029	0.00961	CcSEcCtD
Vemurafenib—Infection—Carmustine—malignant glioma	0.000288	0.00954	CcSEcCtD
Vemurafenib—Anaphylactic shock—Temozolomide—malignant glioma	0.00028	0.00928	CcSEcCtD
Vemurafenib—Infection—Temozolomide—malignant glioma	0.000278	0.00922	CcSEcCtD
Vemurafenib—Nervous system disorder—Temozolomide—malignant glioma	0.000275	0.0091	CcSEcCtD
Vemurafenib—ABCG2—medulla oblongata—malignant glioma	0.000274	0.0178	CbGeAlD
Vemurafenib—Skin disorder—Temozolomide—malignant glioma	0.000272	0.00901	CcSEcCtD
Vemurafenib—Hypotension—Carmustine—malignant glioma	0.000271	0.00897	CcSEcCtD
Vemurafenib—CYP2D6—brainstem—malignant glioma	0.00027	0.0175	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000264	0.00875	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000255	0.00845	CcSEcCtD
Vemurafenib—Decreased appetite—Carmustine—malignant glioma	0.000252	0.00835	CcSEcCtD
Vemurafenib—ABCG2—midbrain—malignant glioma	0.000251	0.0162	CbGeAlD
Vemurafenib—Gastrointestinal disorder—Carmustine—malignant glioma	0.00025	0.00829	CcSEcCtD
Vemurafenib—Constipation—Carmustine—malignant glioma	0.000248	0.00821	CcSEcCtD
Vemurafenib—ABCG2—spinal cord—malignant glioma	0.000245	0.0158	CbGeAlD
Vemurafenib—Decreased appetite—Temozolomide—malignant glioma	0.000243	0.00807	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000242	0.00801	CcSEcCtD
Vemurafenib—Fatigue—Temozolomide—malignant glioma	0.000241	0.008	CcSEcCtD
Vemurafenib—Constipation—Temozolomide—malignant glioma	0.000239	0.00793	CcSEcCtD
Vemurafenib—CYP2D6—telencephalon—malignant glioma	0.000239	0.0155	CbGeAlD
Vemurafenib—ABCC1—cerebellum—malignant glioma	0.000234	0.0152	CbGeAlD
Vemurafenib—ALB—brain—malignant glioma	0.000231	0.0149	CbGeAlD
Vemurafenib—Body temperature increased—Carmustine—malignant glioma	0.000229	0.00759	CcSEcCtD
Vemurafenib—Body temperature increased—Temozolomide—malignant glioma	0.000221	0.00734	CcSEcCtD
Vemurafenib—Hypersensitivity—Carmustine—malignant glioma	0.000213	0.00707	CcSEcCtD
Vemurafenib—Asthenia—Carmustine—malignant glioma	0.000208	0.00689	CcSEcCtD
Vemurafenib—Hypersensitivity—Temozolomide—malignant glioma	0.000206	0.00684	CcSEcCtD
Vemurafenib—Asthenia—Temozolomide—malignant glioma	0.000201	0.00666	CcSEcCtD
Vemurafenib—Diarrhoea—Carmustine—malignant glioma	0.000198	0.00657	CcSEcCtD
Vemurafenib—Pruritus—Temozolomide—malignant glioma	0.000198	0.00656	CcSEcCtD
Vemurafenib—ABCG2—cerebellum—malignant glioma	0.000194	0.0126	CbGeAlD
Vemurafenib—Dizziness—Carmustine—malignant glioma	0.000192	0.00635	CcSEcCtD
Vemurafenib—Diarrhoea—Temozolomide—malignant glioma	0.000192	0.00635	CcSEcCtD
Vemurafenib—ABCC1—brain—malignant glioma	0.00019	0.0123	CbGeAlD
Vemurafenib—Dizziness—Temozolomide—malignant glioma	0.000185	0.00614	CcSEcCtD
Vemurafenib—Vomiting—Carmustine—malignant glioma	0.000184	0.0061	CcSEcCtD
Vemurafenib—Rash—Carmustine—malignant glioma	0.000183	0.00605	CcSEcCtD
Vemurafenib—Dermatitis—Carmustine—malignant glioma	0.000182	0.00605	CcSEcCtD
Vemurafenib—Headache—Carmustine—malignant glioma	0.000181	0.00602	CcSEcCtD
Vemurafenib—Vomiting—Temozolomide—malignant glioma	0.000178	0.0059	CcSEcCtD
Vemurafenib—Rash—Temozolomide—malignant glioma	0.000177	0.00585	CcSEcCtD
Vemurafenib—Dermatitis—Temozolomide—malignant glioma	0.000176	0.00585	CcSEcCtD
Vemurafenib—Headache—Temozolomide—malignant glioma	0.000175	0.00581	CcSEcCtD
Vemurafenib—Nausea—Carmustine—malignant glioma	0.000172	0.0057	CcSEcCtD
Vemurafenib—Nausea—Temozolomide—malignant glioma	0.000166	0.00551	CcSEcCtD
Vemurafenib—ABCG2—brain—malignant glioma	0.000158	0.0102	CbGeAlD
Vemurafenib—CYP3A4—central nervous system—malignant glioma	0.000138	0.00895	CbGeAlD
Vemurafenib—CYP2D6—central nervous system—malignant glioma	0.000136	0.00881	CbGeAlD
Vemurafenib—CYP2D6—cerebellum—malignant glioma	0.000133	0.00861	CbGeAlD
Vemurafenib—CYP2D6—brain—malignant glioma	0.000108	0.00699	CbGeAlD
Vemurafenib—ABCC1—Disease—PTPN11—malignant glioma	7.95e-06	6.45e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP2C18—malignant glioma	7.94e-06	6.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BCAN—malignant glioma	7.9e-06	6.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTK2—malignant glioma	7.88e-06	6.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PIK3CA—malignant glioma	7.87e-06	6.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—malignant glioma	7.84e-06	6.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTEN—malignant glioma	7.81e-06	6.34e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	7.78e-06	6.32e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTT1—malignant glioma	7.78e-06	6.31e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CD—malignant glioma	7.77e-06	6.31e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2B6—malignant glioma	7.76e-06	6.3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HES1—malignant glioma	7.74e-06	6.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KRAS—malignant glioma	7.71e-06	6.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NCOR1—malignant glioma	7.7e-06	6.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—BRAF—malignant glioma	7.67e-06	6.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—malignant glioma	7.62e-06	6.18e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—BRAF—malignant glioma	7.6e-06	6.17e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT2—malignant glioma	7.56e-06	6.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT2—malignant glioma	7.47e-06	6.06e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FGF2—malignant glioma	7.44e-06	6.04e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CAV1—malignant glioma	7.44e-06	6.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CB—malignant glioma	7.41e-06	6.02e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KRAS—malignant glioma	7.41e-06	6.01e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT2—malignant glioma	7.4e-06	6.01e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PDGFRA—malignant glioma	7.37e-06	5.98e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS1—malignant glioma	7.29e-06	5.92e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CD—malignant glioma	7.26e-06	5.89e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	7.26e-06	5.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CD—malignant glioma	7.17e-06	5.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SPP1—malignant glioma	7.15e-06	5.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL8—malignant glioma	7.12e-06	5.78e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—RAF1—malignant glioma	7.12e-06	5.78e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CD—malignant glioma	7.11e-06	5.77e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7.1e-06	5.77e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—IDH1—malignant glioma	7.09e-06	5.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PIK3CA—malignant glioma	7.09e-06	5.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BCL2—malignant glioma	7.06e-06	5.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNG—malignant glioma	7e-06	5.68e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—STAT3—malignant glioma	6.98e-06	5.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MDM2—malignant glioma	6.96e-06	5.65e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGF2—malignant glioma	6.95e-06	5.64e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CB—malignant glioma	6.95e-06	5.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FGF2—malignant glioma	6.87e-06	5.58e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SPHK1—malignant glioma	6.86e-06	5.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ERBB2—malignant glioma	6.86e-06	5.57e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FGF2—malignant glioma	6.81e-06	5.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2—malignant glioma	6.81e-06	5.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PIK3CA—malignant glioma	6.81e-06	5.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TERT—malignant glioma	6.78e-06	5.51e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—BCHE—malignant glioma	6.77e-06	5.5e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CG—malignant glioma	6.77e-06	5.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CB—malignant glioma	6.77e-06	5.5e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2C18—malignant glioma	6.73e-06	5.46e-05	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—AKT1—malignant glioma	6.72e-06	5.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SLC5A5—malignant glioma	6.69e-06	5.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PDGFB—malignant glioma	6.62e-06	5.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGFR1—malignant glioma	6.59e-06	5.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—AKT1—malignant glioma	6.56e-06	5.32e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CAV1—malignant glioma	6.54e-06	5.31e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PPARG—malignant glioma	6.54e-06	5.31e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MDM2—malignant glioma	6.5e-06	5.28e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—malignant glioma	6.49e-06	5.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HIF1A—malignant glioma	6.49e-06	5.27e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RAF1—malignant glioma	6.48e-06	5.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—malignant glioma	6.43e-06	5.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MDM2—malignant glioma	6.43e-06	5.22e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTT1—malignant glioma	6.42e-06	5.21e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ERBB2—malignant glioma	6.41e-06	5.21e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2—malignant glioma	6.38e-06	5.18e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MDM2—malignant glioma	6.37e-06	5.17e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—IDH2—malignant glioma	6.37e-06	5.17e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—RAF1—malignant glioma	6.35e-06	5.15e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—malignant glioma	6.35e-06	5.15e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	6.34e-06	5.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERBB2—malignant glioma	6.34e-06	5.14e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CB—malignant glioma	6.33e-06	5.14e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	6.33e-06	5.14e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERBB2—malignant glioma	6.28e-06	5.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CAV1—malignant glioma	6.27e-06	5.09e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	6.27e-06	5.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CB—malignant glioma	6.25e-06	5.08e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—malignant glioma	6.24e-06	5.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—malignant glioma	6.22e-06	5.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KDR—malignant glioma	6.2e-06	5.04e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CB—malignant glioma	6.2e-06	5.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—malignant glioma	6.2e-06	5.03e-05	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—RAF1—malignant glioma	6.16e-06	5e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—malignant glioma	6.14e-06	4.99e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—malignant glioma	6.08e-06	4.94e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS1—malignant glioma	6.02e-06	4.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KRAS—malignant glioma	6e-06	4.87e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2B6—malignant glioma	5.99e-06	4.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—F2—malignant glioma	5.97e-06	4.85e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FN1—malignant glioma	5.97e-06	4.85e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CG—malignant glioma	5.96e-06	4.84e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CD—malignant glioma	5.95e-06	4.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BAD—malignant glioma	5.9e-06	4.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTEN—malignant glioma	5.85e-06	4.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOTCH1—malignant glioma	5.84e-06	4.74e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—malignant glioma	5.82e-06	4.73e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—malignant glioma	5.81e-06	4.72e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—malignant glioma	5.79e-06	4.7e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	5.78e-06	4.69e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—malignant glioma	5.75e-06	4.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD80—malignant glioma	5.72e-06	4.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APC—malignant glioma	5.71e-06	4.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CG—malignant glioma	5.71e-06	4.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGF—malignant glioma	5.65e-06	4.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTPN11—malignant glioma	5.61e-06	4.56e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—BCHE—malignant glioma	5.59e-06	4.54e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	5.58e-06	4.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—malignant glioma	5.56e-06	4.51e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC5A5—malignant glioma	5.52e-06	4.49e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PIK3CA—malignant glioma	5.51e-06	4.47e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—malignant glioma	5.5e-06	4.47e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—IDH1—malignant glioma	5.48e-06	4.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTEN—malignant glioma	5.47e-06	4.44e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.47e-06	4.44e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTT1—malignant glioma	5.44e-06	4.42e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—malignant glioma	5.43e-06	4.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTEN—malignant glioma	5.4e-06	4.39e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—malignant glioma	5.39e-06	4.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BRAF—malignant glioma	5.37e-06	4.36e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTEN—malignant glioma	5.36e-06	4.35e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SPHK1—malignant glioma	5.3e-06	4.3e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAT—malignant glioma	5.24e-06	4.26e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CD—malignant glioma	5.24e-06	4.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—malignant glioma	5.23e-06	4.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT2—malignant glioma	5.23e-06	4.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—malignant glioma	5.21e-06	4.23e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2C18—malignant glioma	5.19e-06	4.21e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CB—malignant glioma	5.19e-06	4.21e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—malignant glioma	5.14e-06	4.18e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS1—malignant glioma	5.1e-06	4.14e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	5.08e-06	4.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CD—malignant glioma	5.02e-06	4.08e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NCOR1—malignant glioma	4.95e-06	4.02e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—malignant glioma	4.94e-06	4.01e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—malignant glioma	4.92e-06	3.99e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—malignant glioma	4.89e-06	3.97e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—malignant glioma	4.83e-06	3.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGF2—malignant glioma	4.81e-06	3.9e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—malignant glioma	4.79e-06	3.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—malignant glioma	4.76e-06	3.86e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—BCHE—malignant glioma	4.74e-06	3.85e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC5A5—malignant glioma	4.68e-06	3.8e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—malignant glioma	4.61e-06	3.74e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CB—malignant glioma	4.57e-06	3.71e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—malignant glioma	4.54e-06	3.69e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—malignant glioma	4.53e-06	3.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—malignant glioma	4.52e-06	3.67e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—malignant glioma	4.5e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MDM2—malignant glioma	4.5e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—malignant glioma	4.49e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—malignant glioma	4.49e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—malignant glioma	4.48e-06	3.64e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—malignant glioma	4.45e-06	3.61e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—malignant glioma	4.45e-06	3.61e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—malignant glioma	4.44e-06	3.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—malignant glioma	4.44e-06	3.6e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	4.43e-06	3.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—malignant glioma	4.39e-06	3.57e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	4.39e-06	3.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CB—malignant glioma	4.38e-06	3.55e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—malignant glioma	4.35e-06	3.53e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAT—malignant glioma	4.33e-06	3.52e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—malignant glioma	4.24e-06	3.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—malignant glioma	4.21e-06	3.42e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—malignant glioma	4.2e-06	3.41e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTT1—malignant glioma	4.2e-06	3.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—malignant glioma	4.15e-06	3.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—malignant glioma	4.13e-06	3.35e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—malignant glioma	4.11e-06	3.34e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—malignant glioma	4.1e-06	3.33e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NCOR1—malignant glioma	4.09e-06	3.32e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAV1—malignant glioma	4.04e-06	3.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—malignant glioma	4.03e-06	3.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—malignant glioma	4.02e-06	3.26e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—malignant glioma	3.95e-06	3.2e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS1—malignant glioma	3.93e-06	3.19e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—malignant glioma	3.86e-06	3.13e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.86e-06	3.13e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	3.82e-06	3.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—malignant glioma	3.81e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—malignant glioma	3.81e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—malignant glioma	3.78e-06	3.07e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—malignant glioma	3.78e-06	3.07e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—malignant glioma	3.77e-06	3.06e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—malignant glioma	3.73e-06	3.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—malignant glioma	3.69e-06	3e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CG—malignant glioma	3.68e-06	2.99e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAT—malignant glioma	3.67e-06	2.98e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BCHE—malignant glioma	3.66e-06	2.97e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC5A5—malignant glioma	3.61e-06	2.93e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—malignant glioma	3.55e-06	2.88e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NCOR1—malignant glioma	3.46e-06	2.81e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—malignant glioma	3.46e-06	2.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—malignant glioma	3.42e-06	2.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—malignant glioma	3.38e-06	2.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—malignant glioma	3.37e-06	2.74e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAV1—malignant glioma	3.33e-06	2.71e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CD—malignant glioma	3.23e-06	2.62e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—malignant glioma	3.16e-06	2.57e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—malignant glioma	3.15e-06	2.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—malignant glioma	3.14e-06	2.55e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—malignant glioma	3.11e-06	2.53e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—malignant glioma	3.09e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—malignant glioma	3.08e-06	2.5e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CG—malignant glioma	3.04e-06	2.47e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—malignant glioma	2.93e-06	2.38e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—malignant glioma	2.91e-06	2.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—malignant glioma	2.91e-06	2.36e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAT—malignant glioma	2.83e-06	2.3e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAV1—malignant glioma	2.82e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CB—malignant glioma	2.82e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—malignant glioma	2.79e-06	2.27e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—malignant glioma	2.78e-06	2.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	2.7e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOR1—malignant glioma	2.67e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CD—malignant glioma	2.67e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—malignant glioma	2.67e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—malignant glioma	2.58e-06	2.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—malignant glioma	2.58e-06	2.1e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CG—malignant glioma	2.57e-06	2.09e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—malignant glioma	2.48e-06	2.02e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—malignant glioma	2.44e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CB—malignant glioma	2.33e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—malignant glioma	2.31e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—malignant glioma	2.27e-06	1.85e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CD—malignant glioma	2.26e-06	1.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—malignant glioma	2.18e-06	1.77e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAV1—malignant glioma	2.18e-06	1.77e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—malignant glioma	2.01e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CG—malignant glioma	1.99e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CB—malignant glioma	1.97e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—malignant glioma	1.95e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—malignant glioma	1.92e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.75e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—malignant glioma	1.72e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—malignant glioma	1.7e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.52e-06	1.24e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—malignant glioma	1.51e-06	1.22e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.42e-06	1.15e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—malignant glioma	1.4e-06	1.14e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—malignant glioma	1.31e-06	1.07e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.2e-06	9.76e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—malignant glioma	1.16e-06	9.41e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—malignant glioma	9.82e-07	7.97e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—malignant glioma	9.27e-07	7.53e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—malignant glioma	7.58e-07	6.15e-06	CbGpPWpGaD
